Discovery of 4-Hydroxy-1,6-Naphthyridine-3-Carbonitrile Derivatives as Novel Pde10A Inhibitors.
Bauer, U., Giordanetto, F., Bauer, M., O'Mahony, G., Johansson, K.E., Knecht, W., Hartleib-Geschwindner, J., Carlsson, E.T., Enroth, C.(2012) Bioorg Med Chem Lett 22: 1944
- PubMed: 22321214 
- DOI: https://doi.org/10.1016/j.bmcl.2012.01.046
- Primary Citation of Related Structures:  
4AEL - PubMed Abstract: 
A series of 1,6-naphthyridine-based compounds was synthesized as potent phosphodiesterase 10A (PDE10A) inhibitors. Structure-based chemical modifications of the discovered chemotype served to further improve potency and selectivity over DHODH, laying the foundation for future optimization efforts.
Organizational Affiliation: 
AstraZeneca, R&D Mölndal, Pepparedsleden 1, S-431 83 Mölndal, Sweden. udo.bauer@astrazeneca.com